source
- Dimerix acquires Mission’s acute kidney injury candidate for $5 million upfrontDimerix announced it has signed a deal to acquire a kidney injury drug candidate from Mission Therapeutics. The asset is ready to enter Phase 2 trials for the treatment of acute kidney injury. Und…
- Sonothera touts ultrasound gene-delivery platform for Duchenne, but experts remain skepticalSonothera, a California startup, says its ultrasound‑based technology can deliver therapeutic genes into cells, a method it believes could treat Duchenne muscular dystrophy and other genetic disord…